Cargando…
CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE
OBJECTIVE: To report the stabilization of urinary glycosaminoglicans (GAG) excretion and clinical improvements in patients with mucopolysaccharidosis type I (MPS I) under an alternative dose regimen of laronidase of 1.2 mg/kg every other week. METHODS: We participated in a dose-optimization trial fo...
Autores principales: | Kyosen, Sandra Obikawa, Toma, Leny, Nader, Helena Bonciani, Braga, Marion Coting, Pereira, Vanessa Gonçalves, Canossa, Sueli, Pesquero, João Bosco, D’Almeida, Vânia, Martins, Ana Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade de Pediatria de São Paulo
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868559/ https://www.ncbi.nlm.nih.gov/pubmed/31090850 http://dx.doi.org/10.1590/1984-0462/;2019;37;3;00010 |
Ejemplares similares
-
A New Mutation in IDS Gene Causing Hunter Syndrome: A Case Report
por: Gomes, Caio Perez, et al.
Publicado: (2020) -
Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series
por: Horovitz, Dafne Dain Gandelman, et al.
Publicado: (2016) -
Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships
por: Al-Sannaa, Nouriya A., et al.
Publicado: (2015) -
Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts
por: Vicente, Carolina Meloni, et al.
Publicado: (2013) -
The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis()
por: Dualibi, Ana Paula Fiuza Funicello, et al.
Publicado: (2015)